Articles tagged with Assays
Researchers developed multimodal models integrating imaging, clinical, and molecular data from TAILORx tissue biorepository for early-stage breast cancer. The models demonstrated enhanced prognostic performance compared to existing methods, highlighting their potential for personalized treatment decision-making.
Researchers have developed a new molecular test to identify Lyme disease earlier and more accurately than traditional methods. The test can detect as few as five bacterial cells and has an estimated sensitivity of 90.9%, making it a potential new avenue for testing Lyme disease.
Researchers found that compounds inhibiting bitter taste receptors, such as (R)-(-)-carvone, can reduce the bitter aftertaste of artificial sweeteners like saccharin and acesulfame K. This discovery has potential applications in food products to enhance palatability.
The journal features novel FAK-paxillin inhibitors, a venom toxin screening platform, and AI-driven solubility prediction for compound discovery. SLAS Discovery highlights innovative technologies to understand and treat human disease.
A high-throughput neutralisation assay reveals how individual immunity gaps shape flu strain success, highlighting personalised immunity and its impact on virus evolution. The study used large-scale sequencing to quantify antibody responses against circulating H3N2 flu strains in children and adults.
A new method called FAIRY uses a dye to rapidly determine whether a virus is infectious or non-infectious. The assay has been evaluated against various viruses and confirmed its potential for screening disinfectants and antivirals.
Researchers assess role of liquid-liquid phase separation drivers in cell division, revealing poor predictive power of established assays. Theoretical models fail to accurately predict protein interactions and localization in the complex cellular environment.
The SLAS Technology October 2023 issue focuses on reducing laboratory automation waste through machine learning and novel systems. Researchers adapt technological advancements for life sciences exploration and experimentation, enabling improved biomedical research and development.
The latest issue of SLAS Discovery features novel technologies and approaches to develop and characterize chemical and biological tools for human disease treatment. The journal reports on high-throughput screening-related research, including fluorescence polarization assay use and glycomimetics.
A Phase 3 trial found that mailing HPV self-collection kits and scheduling assistance increased cervical cancer screenings among under-screened, underserved women. The study demonstrated the effectiveness of this approach in breaking down access barriers to screening.
A new method developed by Flatiron Institute researchers can diagnose COVID-19 with near-perfect accuracy, even in asymptomatic patients. The technique monitors the body's molecular response to a viral attack and measures mRNA molecules to identify an immune response.
Researchers at Nagoya University have identified 2,6-dihalopurines as a new class of stomatal opening inhibitors, potentially involving LRX3-5 and RALF peptide. This discovery may lead to the development of new agrochemicals and chemical biology research applications.
Researchers at KAUST have discovered the molecular mechanisms of DNA repair by studying the interaction between two enzymes, Lig1 and PCNA. Lig1 seals nicks in DNA by attaching to a ring-shaped protein called PCNA, which dislodges another enzyme FEN1 to prepare for sealing.
Researchers developed a novel method to visualize proteins secreted by cells with high resolution, using plasmonic-fluor technology. The FluoroDOT assay is versatile, low-cost and adaptable, providing a more comprehensive look at these proteins.
Researchers have developed a novel fusion protein that enables the detection of SARS-CoV-2 antibodies using widely available glucose meters. The test was validated on various patient samples and found to be as accurate as four different ELISAs.
Researchers found that sugar-decorated proteins in mucus can bind to the coronavirus, keeping it from infecting cells. This discovery may explain why SARS-CoV-2 is more likely to spread through airborne droplets rather than surface transmission.
Researchers have developed a highly sensitive immuno-CRISPR assay to detect acute kidney rejection in urine, potentially allowing for early diagnosis without invasive biopsy. The test uses CRISPR/Cas12a gene editing technology to identify biomarkers of rejection, such as CXCL9, with improved sensitivity compared to existing methods.
A new approach has been developed to identify proteins affected by pollutants and chemicals, allowing for early detection of harmful biological effects. The method, called PISA, can be used to study the interactions between chemicals and proteins, revealing potential toxicity pathways.